Literature DB >> 11752704

Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge.

Thorsten U Vogel1,2, Brigitte E Beer2, Jan Zur Megede2, Hans-Georg Ihlenfeldt3, Günther Jung3, Silke Holzammer2, David I Watkins1, John D Altman4, Reinhard Kurth2, Stephen Norley2.   

Abstract

Lipopeptides which carry the N-terminal moiety tripalmitoyl-S-glyceryl-cysteinyl-seryl-seryl (P(3)CSS) have been shown to have effective adjuvant and transmembrane carrier properties. To test the ability of these constructs to immunize against simian immunodeficiency virus [(SIV)(mac)] infection, rhesus macaques, prescreened for expression of the Mamu-A*01 MHC class I molecule, were immunized at regular intervals with lipopeptides corresponding to known SIV(mac) CTL epitopes alone or in combination with multiple antigenic peptides corresponding to neutralizing epitopes. Both humoral and CTL responses were elicited and the monkeys, along with non-immunized control animals, were challenged intravenously with 20 MID(50) of the homologous, uncloned SIV(mac251-32H) grown in rhesus monkey PBMC. Although none of the monkeys were protected from infection, most demonstrated an anamnestic CTL response with epitope-specific CTL precursor frequencies reaching as high as 1 in 20 total PBMC as measured by limiting dilution CTL assay or 25% of all CD8(+) T-cells using tetrameric MHC-I/peptide complexes. A significant inverse correlation between the levels of CTLp and the number of infected cells in circulation was observed. However, no such correlation with the plasma viral load (RNA copies/ml) was evident.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752704     DOI: 10.1099/0022-1317-83-1-81

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes.

Authors:  Miranda Z Smith; C Jane Dale; Robert De Rose; Ivan Stratov; Caroline S Fernandez; Andrew G Brooks; Jason Weinfurter; Kendall Krebs; Cara Riek; David I Watkins; David H O'connor; Stephen J Kent
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Authors:  Richard Stebbings; Neil Berry; Herman Waldmann; Pru Bird; Geoff Hale; Jim Stott; David North; Robin Hull; Joanna Hall; Jenny Lines; Stuart Brown; Nikki D'Arcy; Leanne Davis; William Elsley; Cherry Edwards; Deborah Ferguson; Jane Allen; Neil Almond
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.

Authors:  Adrian B McDermott; Jacque Mitchen; Shari Piaskowski; Ivna De Souza; Levi J Yant; Jason Stephany; Jessica Furlott; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Derringer desirability and kinetic plot LC-column comparison approach for MS-compatible lipopeptide analysis.

Authors:  Matthias D'Hondt; Frederick Verbeke; Sofie Stalmans; Bert Gevaert; Evelien Wynendaele; Bart De Spiegeleer
Journal:  J Pharm Anal       Date:  2013-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.